ES2193266T3 - Compuestos de feniletanolamina, utiles como agonistas de beta3, procedimiento para su produccion e intermedios de su produccion. - Google Patents
Compuestos de feniletanolamina, utiles como agonistas de beta3, procedimiento para su produccion e intermedios de su produccion.Info
- Publication number
- ES2193266T3 ES2193266T3 ES96935424T ES96935424T ES2193266T3 ES 2193266 T3 ES2193266 T3 ES 2193266T3 ES 96935424 T ES96935424 T ES 96935424T ES 96935424 T ES96935424 T ES 96935424T ES 2193266 T3 ES2193266 T3 ES 2193266T3
- Authority
- ES
- Spain
- Prior art keywords
- production
- substituted
- represents hydrogen
- lower alkoxy
- intermediates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title abstract 2
- ULSIYEODSMZIPX-UHFFFAOYSA-N phenylethanolamine Chemical class NCC(O)C1=CC=CC=C1 ULSIYEODSMZIPX-UHFFFAOYSA-N 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title 1
- 239000000543 intermediate Substances 0.000 title 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 230000001800 adrenalinergic effect Effects 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical class [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/24—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/36—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE FENILETANOLAMINA REPRESENTADOS MEDIANTE LA FORMULA GENERAL [I]: (DONDE R 1 REPRESENTA HIDROGENO O HALOGENO; R 2 REPRESENTA HIDROGENO, HIDROXILO, ALCOXI INFERIOR, ALCOXI INFERIOR SUSTITUIDO POR UNO O MAS GRUPOS ALCOXICARBONILO O CARBOXI, ALCOXI INFERIOR SUSTITUIDO POR ALQUILAMINOCARBONILO INFERIOR, QUE PUEDE ESTAR SUSTITUIDO POR ALCOXI INFERIOR, ALCOXI INFERIOR SUSTITUIDO POR AMINOCARBONILO CICLICO DE 4 A 6 ATOMOS DE CARBONO, ALCOXICARBONILO O CARBOXI INFERIOR; R 3 REPRESENTA HIDROGENO, HIDROXILO, ALCOXI INFERIOR O ALCOXI INFERIOR SUSTITUIDO POR UNO O DOS GRUPOS ALCOXICARBONILO INFERIOR O CARBOXI; R 2 Y R3 PUEDEN ESTAR UNIDOS ENTRE SI PARA FORMAR METILENDIOXI SUSTITUIDO POR CARBOXI O ALCOXICARBONILO INFERIOR; Y M Y N SON 0 O 1). ASIMISMO, SE INCLUYEN SUS SALES FARMACOLOGICAMENTE ACEPTABLES, QUE PRESENTAN UN POTENTE EFECTO ESTIMULANTE BE 3 AD RENERGICO Y UNA ELEVADA SELECTIVIDAD PARA EL RECEPTOR BE 3 ADRENERGICO, ASI COMO PROCESOS PARA SU PRODUCCION E INTERMEDIARIOS PARA DICHA PRODUCCION.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP27855495 | 1995-10-26 | ||
JP24962296 | 1996-09-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2193266T3 true ES2193266T3 (es) | 2003-11-01 |
Family
ID=26539396
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES96935424T Expired - Lifetime ES2193266T3 (es) | 1995-10-26 | 1996-10-24 | Compuestos de feniletanolamina, utiles como agonistas de beta3, procedimiento para su produccion e intermedios de su produccion. |
Country Status (12)
Country | Link |
---|---|
US (1) | US6069176A (es) |
EP (1) | EP0940387B1 (es) |
JP (1) | JP3926390B2 (es) |
KR (1) | KR100483635B1 (es) |
AT (1) | ATE239694T1 (es) |
AU (1) | AU715216B2 (es) |
CZ (1) | CZ126598A3 (es) |
DE (1) | DE69628051T2 (es) |
ES (1) | ES2193266T3 (es) |
HU (1) | HUP9802318A3 (es) |
NO (1) | NO981858L (es) |
WO (1) | WO1997015549A1 (es) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000068208A (ko) * | 1996-08-19 | 2000-11-25 | 간자와 무츠와 | 빈뇨 및 요실금의 예방·치료제 |
WO1998024754A1 (fr) * | 1996-12-04 | 1998-06-11 | Kureha Kagaku Kogyo Kabushiki Kaisha | Derives de la cyclopentyleamine, leur procede de preparation et bactericides |
WO1999051564A1 (en) * | 1998-04-06 | 1999-10-14 | Fujisawa Pharmaceutical Co., Ltd. | Propanolamine derivatives |
EP0982026B1 (en) * | 1998-08-18 | 2006-05-17 | F. Hoffmann-La Roche Ag | Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers |
DE69931316D1 (de) * | 1998-08-18 | 2006-06-22 | Hoffmann La Roche | Verwendung von Aryl-Cyclohexylamine Derivaten zur Herstellung von NMDA-Rezeptorblockern |
US6828460B2 (en) | 1999-03-22 | 2004-12-07 | Pfizer Inc. | Resorcinol derivatives |
EP1258253A1 (en) * | 2000-01-28 | 2002-11-20 | Asahi Kasei Kabushiki Kaisha | Novel remedies with the use of beta3 agonist |
EP1278716B1 (en) | 2000-04-26 | 2006-08-23 | Warner-Lambert Company LLC | Trans-n-¬4-(4-hydroxyphenyl)cyclohexyl|-3-phenylpropionamide as subtype selective nmda receptor antagonist |
WO2001092204A1 (en) * | 2000-06-01 | 2001-12-06 | Warner-Lambert Company | Cyclohexylamine derivatives as subtype selective nmda receptor antagonists |
ATE301642T1 (de) * | 2000-06-06 | 2005-08-15 | Warner Lambert Co | Bicyclische cyclohexylamine und ihre verwendung als nmda-rezeptor antagonisten |
US6514991B2 (en) * | 2000-07-17 | 2003-02-04 | Wyeth | Phenyl-oxo-tetrahydroquinolin-3-yl beta-3 adrenergic receptor agonists |
US6465501B2 (en) | 2000-07-17 | 2002-10-15 | Wyeth | Azolidines as β3 adrenergic receptor agonists |
US6410734B1 (en) * | 2000-07-17 | 2002-06-25 | Wyeth | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists |
US6506901B2 (en) | 2000-07-17 | 2003-01-14 | Wyeth | Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists |
US6395762B1 (en) | 2000-07-17 | 2002-05-28 | American Home Products Corporation | Phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists |
US6444685B1 (en) | 2000-07-17 | 2002-09-03 | Wyeth | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists |
US6525202B2 (en) * | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
US6509358B2 (en) | 2000-07-17 | 2003-01-21 | Wyeth | Piperidino-phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists |
US6458817B1 (en) | 2000-07-17 | 2002-10-01 | Wyeth | Substituted arylsulfides, arylsulfoxides and arylsulfones as beta-3 adrenergic receptor agonists |
US6498170B2 (en) * | 2000-07-17 | 2002-12-24 | Wyeth | Cyclamine sulfonamides as β-3 adrenergic receptor agonists |
US6537994B2 (en) | 2000-07-17 | 2003-03-25 | Wyeth | Heterocyclic β3 adrenergic receptor agonists |
US6451814B1 (en) | 2000-07-17 | 2002-09-17 | Wyeth | Heterocyclic β-3 adrenergic receptor agonists |
US20040018959A1 (en) * | 2002-05-02 | 2004-01-29 | Randall S. Hickle | System and methods of lipid removal from the body |
GB0217211D0 (en) * | 2002-07-24 | 2002-09-04 | Syngenta Participations Ag | Organic compounds |
US7750029B2 (en) * | 2002-11-07 | 2010-07-06 | Astellas Pharma Inc. | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
EP1424079A1 (en) * | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine |
SI1599468T1 (sl) * | 2003-01-14 | 2008-02-29 | Arena Pharm Inc | 1,2,3-trisubstituirani arilni in heteroarilni derivati kot modulatorji metabolizma ter profilaksa in zdravljenje motenj v zvezi z njim, kot diabetesain hiperglikemije |
EP1599468B1 (en) * | 2003-01-14 | 2007-10-03 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
AR045047A1 (es) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
AU2004285289A1 (en) * | 2003-11-03 | 2005-05-12 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha-reductase inhibitor |
US20050250944A1 (en) * | 2004-05-04 | 2005-11-10 | Jian Chen | Synthesis and uses of synephrine derivatives |
EP1799639B1 (en) * | 2004-10-12 | 2013-09-04 | Glenmark Pharmaceuticals S.A. | Novel dipeptidyl peptidase iv inhibitors, pharmaceutical compositions containing them, and process for their preparation |
EP1806335A4 (en) * | 2004-10-20 | 2008-12-03 | Mitsubishi Tanabe Pharma Corp | METHOD FOR PRODUCING A PHENYLETHANOLAMINE COMPOUND AND INTERMEDIATE PRODUCTS THEREFOR |
DOP2006000010A (es) | 2005-01-10 | 2006-07-31 | Arena Pharm Inc | Procedimiento para preparar eteres aromáticos |
MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
WO2007083640A1 (ja) * | 2006-01-18 | 2007-07-26 | Kyorin Pharmaceutical Co., Ltd. | 頻尿及び尿失禁の予防又は治療剤 |
WO2008024787A1 (en) * | 2006-08-23 | 2008-02-28 | Medicinova, Inc. | Method of treatment or prophylaxis of depression |
KR100821567B1 (ko) | 2006-11-01 | 2008-04-15 | 한국화학연구원 | 광학 활성 2-설포닐옥시-1-페닐에탄올 유도체의 제조방법 |
US20080200467A1 (en) * | 2006-11-02 | 2008-08-21 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors |
US8217027B2 (en) * | 2006-12-21 | 2012-07-10 | Abbott Laboratories | Sphingosine-1-phosphate receptor agonist and antagonist compounds |
BRPI0811639A2 (pt) * | 2007-05-31 | 2014-09-30 | Sepracor Inc | Cicloaquilaminas fenil substituídas como inibidores da recaptação de monoamina |
CN101970394B (zh) * | 2007-11-23 | 2015-05-27 | 利奥制药有限公司 | 用于治疗疾病的新的环烃化合物 |
EP2588444A1 (en) * | 2010-06-30 | 2013-05-08 | Leo Pharma A/S | New polymorphic form of a calcimimetic compound |
CN102958907A (zh) * | 2010-06-30 | 2013-03-06 | 利奥制药有限公司 | 钙敏感受体激动化合物的新多晶型 |
US9522129B2 (en) | 2010-08-03 | 2016-12-20 | Velicept Therapeutics, Inc. | Pharmaceutical Combination |
EP2600859A1 (en) | 2010-08-03 | 2013-06-12 | Altherx Inc. | Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder |
US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
KR101871011B1 (ko) | 2010-09-22 | 2018-06-25 | 아레나 파마슈티칼스, 인크. | Gpr119 수용체의 조절제 및 그와 관련된 장애의 치료 |
ES2394349B1 (es) | 2012-08-29 | 2013-11-04 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar |
JP6450660B2 (ja) * | 2014-08-25 | 2019-01-09 | 住友化学株式会社 | 塩、酸発生剤、レジスト組成物及びレジストパターンの製造方法 |
MX2017007054A (es) | 2014-12-03 | 2018-05-02 | Velicept Therapeutics Inc | Composiciones y métodos para usar solabegron de liberación modificada para sintomas del tracto urinario inferior. |
MX2017008925A (es) | 2015-01-06 | 2017-10-11 | Arena Pharm Inc | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. |
PT3310760T (pt) | 2015-06-22 | 2022-11-10 | Arena Pharm Inc | Sal cristalino de l-arginina de ácido (r)-2-(7-(4-ciclopentil-3-(trifluorometil)benziloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para utilização em distúrbios associados a recetores de s1p1 |
IL310527A (en) | 2015-10-23 | 2024-03-01 | B3Ar Therapeutics Inc | Zwitterion solvegron and its uses |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4940226B1 (es) * | 1970-05-02 | 1974-10-31 | ||
US3803232A (en) * | 1970-09-30 | 1974-04-09 | Ciba Geigy Corp | Arylcarboxamidines |
JPS517617B2 (es) * | 1972-08-25 | 1976-03-09 | ||
US4350685A (en) * | 1981-02-06 | 1982-09-21 | Smithkline Corporation | Antiallergic imidodisulfamides |
JPS62198639A (ja) * | 1986-02-26 | 1987-09-02 | Takasago Corp | α−アリ−ルカルボニル誘導体の製造法 |
US4755505A (en) * | 1987-08-18 | 1988-07-05 | American Home Products Corporation | 1-[2-(dialkylamino)alkyl]-4,5-dihydro-4-(aryl)-1-benzazocine-2,6(1H,3H)-diones as anti-arrhythmic agents |
JPH0819032B2 (ja) * | 1987-11-20 | 1996-02-28 | 三井東圧化学株式会社 | 2−(4−ヒドロキシフェニル)−シクロヘキサノンの製造方法 |
FR2643076B1 (fr) * | 1989-02-14 | 1991-06-21 | Midy Spa | Carboxyalkyl-ethers de la 2-amino-7-hydroxytetraline |
DE4006937A1 (de) * | 1990-03-06 | 1991-09-12 | Basf Ag | 4-(4-tert.-butylphenyl)cyclohexylamine und diese enthaltende fungizide |
JP2971938B2 (ja) * | 1990-11-01 | 1999-11-08 | ダイセル化学工業株式会社 | 分離剤 |
GB9107827D0 (en) * | 1991-04-12 | 1991-05-29 | Fujisawa Pharmaceutical Co | New ethanolamine derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same |
JP2932330B2 (ja) * | 1991-10-28 | 1999-08-09 | 雪印乳業株式会社 | 含窒素化合物の水素化還元方法 |
DE4210569A1 (de) * | 1992-03-31 | 1993-10-07 | Hoechst Ag | Verwendung von substituierten µ-Hydroxyethylaminen als fungizide Wirkstoffe |
-
1996
- 1996-10-24 EP EP96935424A patent/EP0940387B1/en not_active Expired - Lifetime
- 1996-10-24 WO PCT/JP1996/003097 patent/WO1997015549A1/ja active IP Right Grant
- 1996-10-24 HU HU9802318A patent/HUP9802318A3/hu unknown
- 1996-10-24 US US09/065,077 patent/US6069176A/en not_active Expired - Lifetime
- 1996-10-24 KR KR10-1998-0703029A patent/KR100483635B1/ko not_active IP Right Cessation
- 1996-10-24 DE DE69628051T patent/DE69628051T2/de not_active Expired - Lifetime
- 1996-10-24 CZ CZ981265A patent/CZ126598A3/cs unknown
- 1996-10-24 AT AT96935424T patent/ATE239694T1/de not_active IP Right Cessation
- 1996-10-24 AU AU73358/96A patent/AU715216B2/en not_active Ceased
- 1996-10-24 JP JP51647697A patent/JP3926390B2/ja not_active Expired - Fee Related
- 1996-10-24 ES ES96935424T patent/ES2193266T3/es not_active Expired - Lifetime
-
1998
- 1998-04-24 NO NO981858A patent/NO981858L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
HUP9802318A3 (en) | 2001-04-28 |
KR100483635B1 (ko) | 2005-12-21 |
AU715216B2 (en) | 2000-01-20 |
KR19990067089A (ko) | 1999-08-16 |
NO981858D0 (no) | 1998-04-24 |
EP0940387A1 (en) | 1999-09-08 |
EP0940387A4 (en) | 2000-07-05 |
CZ126598A3 (cs) | 1998-09-16 |
ATE239694T1 (de) | 2003-05-15 |
HUP9802318A2 (hu) | 1999-08-30 |
DE69628051T2 (de) | 2004-02-26 |
EP0940387B1 (en) | 2003-05-07 |
JP3926390B2 (ja) | 2007-06-06 |
AU7335896A (en) | 1997-05-15 |
US6069176A (en) | 2000-05-30 |
NO981858L (no) | 1998-06-24 |
DE69628051D1 (de) | 2003-06-12 |
WO1997015549A1 (fr) | 1997-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2193266T3 (es) | Compuestos de feniletanolamina, utiles como agonistas de beta3, procedimiento para su produccion e intermedios de su produccion. | |
NO20050429L (no) | Substituert kinolin-CCR5-reseptorantagonister | |
GT200200266A (es) | Uso de ureas de benzotiazoles | |
ECSP088154A (es) | Proceso para la preparacion de un compuesto 4-amino-2 (2,6, dioxopiperidin-3-yl) isoindoline-1-3-dione | |
GT200300292A (es) | Derivados de pirimidina para el tratamiento de crecimiento celular anormal | |
DE60229530D1 (de) | Substituierte piperazine als modulatoren des melanocortinrezeptors | |
GT200400020A (es) | Compuestos de triazol utiles en terapia | |
PE20060777A1 (es) | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas | |
CY1109854T1 (el) | Παραγωγα αζαδικυκλο(3.1.0)εξανιου χρησιμα ως ρυθμιστες υποδοχεων d3 ντοπαμινης | |
GT200000011A (es) | Uso de acidos isoxazolcarboxilicos sustituidos y derivados y nuevos materiales. | |
AR034734A1 (es) | Sintesis e intermediarios | |
PE20051095A1 (es) | DERIVADOS 1H-TIENO[2,3-c] PIRAZOL UTILES COMO INHIBIDORES DE QUINASA | |
GT200500317A (es) | Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos | |
PA8575001A1 (es) | Fluorobenzamidas como inhibidores de maob | |
UY27232A1 (es) | Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos | |
BR0301667A (pt) | Processo para a preparação de polìmeros em emulsão com pureza elevada | |
GT200200159A (es) | 2-(3,5-bis-trifluorometil-fenil)-n-[6-(1,1-dioxo-1lambda6-tiomorfolin-4-il)-4-(2-metil o 4-fluoro-2-metil substituido)fenil-piridin-3-il]-n-metil-isobutiramida | |
NO20040388L (no) | Fremgangsmåte for fremstilling av beraprost og salter derav, samt forbindelser som er mellomprodukter i fremgangsmåten | |
BR0316702A (pt) | xprocesso para preparação de (s)-pantoprazol | |
AR047312A1 (es) | Procedimiento para la sintesis de perindopril y de sus sales farmaceuticamente aceptables | |
AR063775A1 (es) | 2- imidazoles sustituidos, un proceso para su obtencion y medicamento preparado en base al compuesto | |
PE20050333A1 (es) | Derivados de 4-indolilsufonamidas como moduladores del receptor de serotonina (5-ht6) | |
IT1285777B1 (it) | Processo di biotrasformazione di composti colchicinoidi nei corrispondenti 3-glicosilderivati | |
GT200200096A (es) | Derivados de 4-aminopirimidina | |
ATE411310T1 (de) | Reinigungsverfahren von moxonidine |